

CURRICULUM VITAE

1. ΠΡΟΣΩΠΙΚΑ ΣΤΟΙΧΕΙΑ

Όνομα: ΓΕΩΡΓΙΟΣ
Επίθετο: ΚΟΛΙΟΣ
Όνομα Πατρός: ΧΡΗΣΤΟΣ
Ημερομηνία γεννήσεως: 05.05.1955
Υπηκοότητα: Ελληνική
Διεύθυνση: Τμήμα Ιατρικής, Δημοκρίτειο Πανεπιστήμιο Θράκης
Δραγάνα, Αλεξανδρούπολη, 68100
Tel: +3025510-30368 FAX: +3025510-30541
E-mail: gkolios@med.duth.gr
Website: <http://utopia.duth.gr/gkolios>

2. ΠΑΡΟΥΣΕΣ ΘΕΣΕΙΣ

- i) Καθηγητής Φαρμακολογίας, Τμήμα Ιατρικής, Δημοκρίτειο Πανεπιστήμιο Θράκης (Δεκέμβριος 2011- σήμερα).

3. ΠΑΝΕΠΙΣΤΗΜΙΑΚΕΣ ΣΠΟΥΔΕΣ

1973-1980 Ιατρική Σχολή Πανεπιστημίου Αθηνών, Πτυχίο Ιατρικής, Μάρτιος 1980.

4. ΜΕΤΑΠΤΥΧΙΑΚΟΙ ΤΙΤΛΟΙ

- i) Τίτλος Ιατρικής Ειδικότητας Γαστρεντερολογίας, Μάιος 1990
- ii) Διδακτορική Διατριβή, Ιατρική Σχολή Πανεπιστημίου Αθηνών, Μάιος 1992.
- iii) Διδακτορική Διατριβή, Σχολή Φαρμακολογίας, Πανεπιστήμιο του Bath, Αγγλία, Φεβρουάριος 1998.

5. ΘΕΣΕΙΣ ΣΤΗΝ ΕΛΛΑΔΑ

- i) Ειδικευόμενος στην Παθολογία, Β' Παθολογική Κλινική του 401 Γεν. Στρατιωτικού Νοσοκομείου Αθηνών, Αύγουστος 1981 – Οκτώβριος 1982.
- ii) Αγροτικός Ιατρός, Κέντρο Υγείας Βουργαρελίου Άρτα, Νοέμβριος 1982- Οκτώβριος 1984.
- iii) Ειδικευόμενος στην Παθολογία, Β' Παθολογική Κλινική του Σισμανογλείου Γενικού Νοσοκομείου Αθηνών, Φεβρουάριος 1985 – Φεβρουάριος 1986.
- iv) Ειδικευόμενος στην Γαστρεντερολογία, Β' Παθολογική Κλινική του Πανεπιστημίου Αθηνών, Ιπποκράτειο Γενικό Νοσοκομείο, Απρίλιος 1986 – Μάρτιος 1990.
- v) Επιμελητής Β' Γαστρεντερολογικό Τμήμα, Ιπποκράτειο Γενικό Νοσοκομείο Αθηνών, Μάιος 1991 – Δεκέμβριος 1997.
- vi) Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστημίου Κρήτης, Μάρτιος 2001 – Μάρτιος 2005.
- vii) Μόνιμος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστημίου Κρήτης, Μάρτιος 2005 – Ιούνιος 2008.
- viii) Αναπλ. Καθηγητής Φαρμακολογίας, Τμήμα Ιατρικής, Δημοκρίτειο Πανεπιστήμιο Θράκης (Ιούνιος 2008 – Δεκέμβριος 2011).

6. ΘΕΣΕΙΣ ΣΤΟ ΕΞΩΤΕΡΙΚΟ

- i) Registrar Gastroenterologist, Royal United Hospital, Bath, England, (Ιούνιος 1990 – Ιούλιος 1991).
- ii) Consultant Gastroenterologist, Royal United Hospital, Bath, England, (Ιανουάριος 1998 – Δεκέμβριος 2000).
- iii) Senior Research Fellow, Department of Pharmacy and Pharmacology, University of Bath, UK (Ιανουάριος 1998 – Δεκέμβριος 2000).

- iv) Researcher, Novartis Pharmaceuticals Ltd United Kingdom, (Ιούνιος 1999 – Νοέμβριος 2000).
- v) Visiting Scientist, Laboratory of Molecular Immunology, Mucosal Immunobiology Section, National Institute of Health (NIH), Bethesda, Maryland, U.S.A. (Ιανουάριος 2007-Νοέμβριος 2007).
- vi) Visiting Scientist, Immunology Institute, Mount Sinai School of Medicine, U.S.A. (Νοέμβριος 2007-Φεβρουάριος 2008).
- vii) Visiting Professor, Department of Pharmacy and Pharmacology, University of Bath, UK (Ιανουάριος 2001 – Δεκέμβριος 2012).

7. ΔΙΟΙΚΗΤΙΚΕΣ ΘΕΣΕΙΣ

- i) Διευθυντής του Εργαστηρίου Φαρμακολογίας του Τμήματος Ιατρικής, Δημοκρίτειο Πανεπιστήμιο Θράκης (Σεπτέμβριος 2008- Ιούνιος 2017).
- ii) Διευθυντής του Εργαστηρίου Κλινικής Φαρμακολογίας του Πανεπιστημιακού Γενικού Νοσοκομείου Αλεξανδρούπολης (Σεπτέμβριος 2008- Ιούνιος 2017).
- iii) Μέλος του Επιστημονικού Συμβουλίου Εγκρίσεων, Α' ΕΣΕ, Εθνικού Οργανισμού Φαρμάκων (Σεπτέμβριος 2008 - Νοέμβριος 2013).
- iv) Διευθυντής Μεταπτυχιακού Προγράμματος «Κλινική Φαρμακολογία-Θεραπευτική», Τμήμα Ιατρικής, Δημοκρίτειο Πανεπιστήμιο Θράκης (Σεπτέμβριος 2009 – Νοέμβριος 2018).
- v) Αναπληρωτής Πρόεδρος, Τμήμα Ιατρικής, Δημοκρίτειο Πανεπιστήμιο Θράκης (Σεπτέμβριος 2013 – Νοέμβριος 2017).
- vi) Αντιπρόεδρος, Ελληνική Γαστρεντερολογική Εταιρεία (Ιανουάριος 2015 - Δεκέμβριος 2017).
- vii) Πρόεδρος Επιτροπής Φαρμάκου, Ινστιτούτου Επιστημονικών Ερευνών Πανελληνίου Ιατρικού Συλλόγου (Δεκέμβριος 2017 – Ιούνιος 2019).
- viii) Αντιπρόεδρος, Επιστημονική Εταιρεία Σπανίων Παθήσεων & Ορφανών Φαρμάκων (Οκτώβριος 2014 - σήμερα).
- ix) Μέλος Συντονιστικής Επιτροπής του Μεταπτυχιακού Προγράμματος «Κλινική Φαρμακολογία-Θεραπευτική», Τμήμα Ιατρικής, Δημοκρίτειο Πανεπιστήμιο Θράκης (Νοέμβριος 2018– σήμερα).

8. ΣΥΜΜΕΤΟΧΗ ΣΕ ΕΠΙΣΤΗΜΟΝΙΚΕΣ ΕΤΑΙΡΕΙΕΣ:

- i) Μέλος της Ελληνικής Γαστρεντερολογικής Εταιρείας (November 1990).
- ii) Μέλος της British Society for Immunology (November 1998).
- iii) Μέλος της European Society of Gastrointestinal and Abdominal Radiology (May 2005).
- iv) Μέλος της Society for Mucosal Immunology (September 2007).
- v) Μέλος της European Crohn's and Colitis Organization (May 2008).
- vi) Μέλος της Ελληνικής Εταιρείας Βασικής και Κλινικής Φαρμακολογίας (Φεβρουάριος 2009).
- vii) Μέλος της Επιστημονική Εταιρεία Σπανίων Παθήσεων & Ορφανών Φαρμάκων (Ιούλιος 2011)

9. ΣΥΜΜΕΤΟΧΗ ΣΕ ΣΥΝΤΑΚΤΙΚΕΣ ΕΠΙΤΡΟΠΕΣ ΠΕΡΙΟΔΙΚΩΝ

1. Annals of Gastroenterology, Associate Editor
2. European Journal of Pharmacology, Editorial Board

10. ΧΡΗΜΑΤΟΔΟΤΗΣΕΙΣ:

- 1994-1995: £ 35.000; National Association for Crohn and Colitis, UK. (Chemokine production by human colonic epithelial cells in inflammatory bowel disease).

- 1995-1998: Drachma 3.000.000; Hellenic Society of Gastroenterology. (Chemokine expression in the mucosa of inflammatory bowel disease patients; modulation by T-cell derived cytokines).
- 1996-1997: £55,000, Astra Foundation, UK. (Mechanisms of mucosal injury in inflammatory bowel disease).
- 1997-1998: £55,000; Astra Foundation, UK (Regulation of chemokines and inducible nitric oxide synthase by cytokines in Inflammatory Bowel Disease-IBD).
- 1999-2000: £ 120,000; Novartis, UK (The role of chemokines in the fibrotic process in IBD).
- 2002-2003: £ 15,000; Wellcome Trust, UK (Investigate the cross-talk between colonic epithelial cells, IEL and myofibroblasts and its relevance to IBD).
- 2005-2007: € 45,200, European structural and investment funds (ESIF) (The impact of chemokines in the fibrotic process of Crohn's disease; the role of myofibroblasts).
- 2006-2009: € 12,000; Greek Ministry of Health (The regulatory role of angiogenic and angiostatic CXC chemokines on colon cancer. Factors regulating the tumor growth and metastasis).
- 2009-2015: € 130,000; GlaxoSmithKline, Greece (Inflammatory mediators and cell populations interplay in the pathogenesis of idiopathic pulmonary fibrosis and pulmonary hypertension), in collaboration with Professor D. Bouros, DUTH, Greece.
- 2013-2015: € 95,000; BBMRI (Biobanking and Biomolecular Resources Research Infrastructure), National Strategic Reference Framework, Greece/European Union.
- 2018: € 10,000; The Hellenic Group for the Study of IBD (Isolation and biobanking of myofibroblasts from IBD patients in the BBMRI-GR biobank in order to study post-inflammatory fibrosis).
- 2018-2020: € 24,000; Kleon Tsetis Foundation, Athens Greece (Gut-kidney axis in fibrosis; the role of microbiome and probiotics (PRObiotics in Gut and RENal Scarring).
- 2019-2022: € 40,000; BBMRI (Biobanking and Biomolecular Resources Research Infrastructure), National Strategic Reference Framework, Greece/European Union.
- 2019-2022: € 360,000, Tithon Biotech Inc, San Diego, California, USA. (Study of anti-inflammatory and/or anti-fibrotic properties of newly synthesized peptides).
- 2020-2023 € 2,750,000; Operational Program “Competitiveness, Entrepreneurship & Innovation” (EPAnEK); Development of Centre of Excellence in Pharmaceutical Studies and Precision Medicine. in collaboration with Professor E. Manolopoulos, DUTH, Greece.

11. ΒΡΑΒΕΥΣΕΙΣ:

- **2006:** 1st prize (€ 1,500) FALK Foundation Symposium 153, Immunoregulation in Inflammatory Bowel Diseases for the work “ *Expression of a spliced variant of CXCR3 chemokine receptor and its chemokine ligands in Crohn's disease patients; a regulatory effect of cytokines*”, May 6-7, 2006, Berlin Germany.
- **2013:** 3rd prize (€ 10,000) in SFEE Innovation Project, with a project aiming “*to unravel the potential of using adipose-derived adult stem cells for autologous transplantation, in an effort to combat incurable lung diseases*”, November 24, 2013, Athens Greece,
- **2014:** National Scholar Award at 22nd United European Gastroenterology Week for the work “*primary intestinal myofibroblasts express the TNF-like cytokine TLIA/TNFSF15 following stimulation with pro-inflammatory mediators*”, October 18-22, 2014, Vienna Austria.
- **2018:** FALK Foundation Symposium 210, Crossing new Borders in IBD. Distinction for the work “*Cytokine receptor profiling in human colonic subepithelial myofibroblasts: a differential effect of Th polarization associated cytokines in intestinal fibrosis*” April 20-21, 2018, Lisbon Portugal.

12. Publications:

1. PhD Thesis:	2
2. Books:	1
3. Publications in PubMed:	109
4. Total Impact factor (PubMed):	470.276
5. Μέσος Impact factor (PubMed):	4.314

13. ΔΗΜΟΣΙΕΥΣΕΙΣ (PubMed)

1. **Kolios G**, Kaloterakis A, Filiotou A, Nakos A, Hadziyannis S. Gastroscopic findings in Mediterranean Kaposi's sarcoma (non-AIDS). *Gastrointestinal Endoscopy*. 1995; 42:336-339.
2. **Kolios G**, Brown Z, Robson RL, Robertson DA, Westwick J. Inducible nitric oxide synthase activity and expression in a human colonic epithelial cell line, HT-29. *British Journal of Pharmacology*. 1995; 116:2866-2872.
3. **Kolios G**, Robertson DA, Jordan NJ, Minty A, Caput D, Ferrara P, Westwick J. Interleukin-8 production by the human colon epithelial cell line HT-29: modulation by interleukin-13. *British Journal of Pharmacology*. 1996; 119:351-359.
4. Wright K, Ward SG, **Kolios G**, Westwick J. Activation of phosphatidylinositol 3-kinase by interleukin-13. An inhibitory signal for inducible nitric-oxide synthase expression in epithelial cell line HT-29. *Journal of Biological Chemistry*. 1997; 272:12626-12633.
5. Davis AJ, **Kolios G**, Alveyn CG, Robertson DA. Antibiotic prophylaxis for ERCP: a comparison of oral ciprofloxacin with intravenous cephazolin in the prophylaxis of high-risk patients. *Alimentary Pharmacology & Therapeutics*. 1998; 12:207-11.
6. **Kolios G**, Rooney N, Murphy CT, Robertson DA, Westwick J. Expression of inducible nitric oxide synthase activity in human colon epithelial cells: modulation by T lymphocyte derived cytokines. *Gut*. 1998; 43:56-63.
7. **Kolios G**, Petoumenos C, Nakos A. Mediators of inflammation: production and implication in inflammatory bowel disease. *Hepato-Gastroenterology*. 1998; 45:1601-1609.
8. **Kolios G**, Wright KL, Jordan NJ, Leithead JB, Robertson DA, Westwick J. C-X-C and C-C chemokine expression and secretion by the human colonic epithelial cell line, HT-29: differential effect of T lymphocyte-derived cytokines. *European Journal of Immunology*. 1999; 29:530-536.
9. Wright K, **Kolios G**, Westwick J, Ward SG. Cytokine-induced apoptosis in epithelial HT-29 cells is independent of nitric oxide formation. Evidence for an interleukin-13-driven phosphatidylinositol 3-kinase-dependent survival mechanism. *Journal of Biological Chemistry*. 1999; 274:17193-17201.
10. Jordan NJ, **Kolios G**, Abbot SE, Sinai MA, Thompson DA, Petraki K, Westwick J. Expression of functional CXCR4 chemokine receptors on human colonic epithelial cells. *Journal of Clinical Investigation*. 1999; 104:1061-1069.
11. **Kolios G**, Wright KL, Linehan JD, Robertson DA, Westwick J. Interleukin-13 inhibits nitric oxide production in human colonic mucosa. *Hepato-Gastroenterology*. 2000; 47:714-717.
12. Weaver SA, Russo MP, Wright KL, **Kolios G**, Jobin C, Robertson DA, Ward SG. Regulatory role of phosphatidylinositol 3-kinase on TNF-alpha-induced cyclooxygenase 2 expression in colonic epithelial cells. *Gastroenterology*. 2001; 120:1117-1127.
13. **Kolios G**, Valatas V, Psilopoulos D, Petraki K, Kouroumalis E. Depletion of non-specific esterase activity in the colonic mucosa of patients with ulcerative colitis. *European Journal of Clinical Investigation*. 2002; 32:265-273.

14. Valatas V, Xidakis C, Roumpaki H, **Kolios G**, Kouroumalis EA. Isolation of rat Kupffer cells: a combined methodology for highly purified primary cultures. *Cell Biology International*. 2003; 27:67-73.
15. Valatas V, **Kolios G**, Manousou P, Notas G, Xidakis C, Diamantis I, Kouroumalis E. Octreotide regulates CC but not CXC LPS-induced chemokine secretion in rat Kupffer cells. *British Journal of Pharmacology*. 2004; 141:477-487.
16. Xidakis C, **Kolios G**, Valatas V, Notas G, Mouzas I, Kouroumalis E. Effect of octreotide on apoptosis-related proteins in rat Kupffer cells: a possible anti-tumour mechanism. *Anticancer Research*. 2004; 24:833-841.
17. Wright KL, Weaver SA, Patel K, Coopman K, Feeney M, **Kolios G**, Robertson DA, Ward SG. Differential regulation of prostaglandin E biosynthesis by interferon-gamma in colonic epithelial cells. *British Journal of Pharmacology*. 2004; 141:1091-1097.
18. Vasilaki A, Papadaki T, Notas G, **Kolios G**, Mastrodimou N, Hoyer D, Tsilimbaris M, Kouroumalis E, Pallikaris I, Thermos K. Effect of somatostatin on nitric oxide production in human retinal pigment epithelium cell cultures. *Investigative Ophthalmology & Visual Science*. 2004; 45:1499-1506.
19. Notas G, **Kolios G**, Mastrodimou N, Kampa M, Vasilaki A, Xidakis C, Castanas E, Thermos K, Kouroumalis E. Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors. *Journal of Hepatology*. 2004; 40:792-798.
20. Valatas V, **Kolios G**, Manousou P, Xidakis C, Notas G, Ljumovic D, Kouroumalis EA. Secretion of inflammatory mediators by isolated rat Kupffer cells: the effect of octreotide. *Regulatory Peptides*. 2004; 120:215-225.
21. Koutroubakis IE, Theodoropoulou A, Xidakis C, Sfiridaki A, Notas G, **Kolios G**, Kouroumalis EA. Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease. *European Journal of Gastroenterology & Hepatology*. 2004; 16:1147-1152.
22. **Kolios G**, Valatas V, Ward SG. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. *Immunology*. 2004; 113:427-437.
23. Linehan JD, **Kolios G**, Valatas V, Robertson DA, Westwick J. Effect of corticosteroids on nitric oxide production in inflammatory bowel disease: are leukocytes the site of action? *American Journal of Physiology. Gastrointestinal and Liver Physiology*. 2005; 288:G261-G267.
24. Dimoulios P, **Kolios G**, Notas G, Matrella E, Xidakis C, Koulentaki M, Tsagarakis N, Kouroumalis A, Kouroumalis E. Ursodeoxycholic acid reduces increased circulating endothelin 2 in primary biliary cirrhosis. *Alimentary Pharmacology & Therapeutics*. 2005; 21:227-234.
25. Xidakis C, Ljumovic D, Manousou P, Notas G, Valatas V, **Kolios G**, Kouroumalis E. Production of pro- and anti-fibrotic agents by rat Kupffer cells; the effect of octreotide. *Digestive Diseases and Sciences*. 2005; 50:935-941.
26. Kouroumalis A, Nibbs RJ, Aptel H, Wright KL, **Kolios G**, Ward SG. The chemokines CXCL9, CXCL10, and CXCL11 differentially stimulate G alpha i-independent signaling and actin responses in human intestinal myofibroblasts. *Journal of Immunology*. 2005; 175:5403-5411.
27. Linehan JD, **Kolios G**, Valatas V, Robertson DA, Westwick J. Immunomodulatory cytokines suppress epithelial nitric oxide production in inflammatory bowel disease by acting on mononuclear cells. *Free Radical Biology & Medicine*. 2005; 39:1560-1569.
28. **Kolios G**, Manousou P, Bourikas L, Notas G, Tsagarakis N, Mouzas I, Kouroumalis E. Ciprofloxacin inhibits cytokine-induced nitric oxide production in human colonic epithelium. *European Journal of Clinical Investigation*. 2006; 36:720-729.
29. Charalampopoulos I, Androulidaki A, Minas V, Chatzaki E, Tsatsanis C, Notas G, Xidakis C, **Kolios G**, Kouroumalis E, Margioris AN, Gravanis A. Neuropeptide

- urocortin and its receptors are expressed in rat Kupffer cells. *Neuroendocrinology*. 2006; 84:49-57.
30. **Kolios G**, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. *World Journal of Gastroenterology*. 2006; 12:7413-7420.
 31. **Kolios G**, Kotzampassi K, Manousou P, Paramythiotis D, Papanastasiou H, Drygiannakis I, Notas G, Tsagarakis N, Eleftheriadis E, Kouroumalis E. Enteral nutrition affects nitric oxide production in peripheral blood and liver after a postoperative lipopolysaccharide-induced endotoxemia in rats. *Nutrition*. 2007; 23:575-581.
 32. Xidakis C, Mastrodimou N, Notas G, Renieri E, **Kolios G**, Kouroumalis E, Thermos K. RT-PCR and immunocytochemistry studies support the presence of somatostatin, cortistatin and somatostatin receptor subtypes in rat Kupffer cells. *Regulatory Peptides*. 2007; 143:76-82.
 33. Damaskos D, **Kolios G**. Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'. *British Journal of Clinical Pharmacology*. 2008; 65:453-467.
 34. Manousou P, **Kolios G**, Drygiannakis I, Pyrovolaki K, Bourikas L, Papadaki HA, Kouroumalis E. Expression of a splice variant of CXCR3 in Crohn's disease patients; indication for a lymphocyte--epithelial cell interaction. *Journal of Gastroenterology and Hepatology*. 2008; 23:1823-33.
 35. **Kolios G**, Valatas V, Manousou P, Xidakis C, Notas G, Kouroumalis E. Nitric oxide and MCP-1 regulation in LPS activated rat Kupffer cells. *Molecular and Cellular Biochemistry*. 2008; 319:91-98.
 36. Galazios G, Papazoglou D, Tsikouras P, **Kolios G**. Vascular endothelial growth factor gene polymorphisms and pregnancy. *The Journal of Maternal-Fetal & Neonatal Medicine*. 2009; 22:371-378.
 37. Bourikas LA, **Kolios G**, Valatas V, Notas G, Drygiannakis I, Pelagiadis I, Manousou P, Klironomos S, Mouzas IA, Kouroumalis E. Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-beta1 secretion and enhances the anti-proliferative effect of 5-fluorouracil. *British Journal of Pharmacology*. 2009; 157:362-370.
 38. Kotzampassi K, **Kolios G**, Manousou P, Kazamias P, Paramythiotis D, Papavramidis TS, Heliadis S, Kouroumalis E, Eleftheriadis E. Oxidative stress due to anesthesia and surgical trauma: importance of early enteral nutrition. *Molecular Nutrition & Food Research*. 2009; 53:770-779.
 39. Paschos KA, **Kolios G**, Chatzaki E. The corticotropin-releasing factor system in inflammatory bowel disease: prospects for new therapeutic approaches. *Drug Discovery Today*. 2009; 14:713-20.
 40. Kefalakes H, Stylianides TJ, Amanakis G, **Kolios G**. Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? *European Journal of Clinical Pharmacology*. 2009; 65:963-970.
 41. Kapetanakis S, Drygiannakis I, Kazakos K, Papanas N, **Kolios G**, Kouroumalis E, Verettas DA. Serum TGF-beta2 and TGF-beta3 are increased and positively correlated to pain, functionality, and radiographic staging in osteoarthritis. *Orthopedics*. 2010; 33:8.
 42. Tsagarakis NJ, Drygiannakis I, Batistakis AG, **Kolios G**, Kouroumalis EA. A concentration-dependent effect of ursodeoxycholate on apoptosis and caspases activities of HepG2 hepatocellular carcinoma cells. *European Journal of Pharmacology*. 2010; 640:1-7.
 43. Manousou P, **Kolios G**, Valatas V, Drygiannakis I, Bourikas L, Pyrovolaki K, Koutroubakis I, Papadaki HA, Kouroumalis E. Increased expression of chemokine receptor CCR3 and its ligands in ulcerative colitis: the role of colonic epithelial cells in in vitro studies. *Clinical and Experimental Immunology*. 2010; 162:337-347.

44. Tsagarakis NJ, Drygiannakis I, Batistakis AG, **Kolios G**, Kouroumalis EA. Octreotide induces caspase activation and apoptosis in human hepatoma HepG2 cells. *World Journal of Gastroenterology*. 2011; 17:313-321.
45. Kambas K, Chrysanthopoulou A, Kourtzelis I, Skordala M, Mitroulis I, Rafail S, Vradelis S, Sigalas I, Wu YQ, Speletas M, **Kolios G**, Ritis K. Endothelin-1 signaling promotes fibrosis in vitro in a bronchopulmonary dysplasia model by activating the extrinsic coagulation cascade. *Journal of Immunology*. 2011; 186:6568-6575.
46. Tzouvelekis A, Koliakos G, Ntolios P, Baira I, Bouros E, Oikonomou A, Zissimopoulos A, **Kolios G**, Kakagia D, Paspaliaris V, Kotsianidis I, Froudarakis M, Bouros D. Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal. *Journal of Translational Medicine*. 2011; 9:182.
47. Chrysanthopoulou A, Mitroulis I, Kambas K, Skendros P, Kourtzelis I, Vradelis S, **Kolios G**, Aslanidis S, Doumas M, Ritis K. Tissue factor-thrombin signaling enhances the fibrotic activity of myofibroblasts in systemic sclerosis through up-regulation of endothelin receptor A. *Arthritis and Rheumatism*. 2011; 63:3586-97.
48. Tzouvelekis A, Bouros E, Oikonomou A, Ntolios P, Zacharis G, **Kolios G**, Bouros D. Effect and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis. *Pulmonary Medicine*. 2011; 2011:849035.
49. Tzouvelekis A, Galanopoulos N, Bouros E, **Kolios G**, Zacharis G, Ntolios P, Koulelidis A, Oikonomou A, Bouros D. Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. *Pulmonary Medicine*. 2012; 2012:143637.
50. Domvri K, Zarogoulidis P, Porpodis K, Koffa M, Lambropoulou M, Kakolyris S, **Kolios G**, Zarogoulidis K, Chatzaki E. Gene therapy in liver diseases: state-of-the-art and future perspectives. *Current Gene Therapy*. 2012; 12(6):463-483.
51. **Kolios G**, Moodley Y. Introduction to stem cells and regenerative medicine. *Respiration*. 2013; 85:3-10.
52. Chatzaki E, Anton PA, Million M, Lambropoulou M, Constantinidis T, **Kolios G**, Taché Y, Grigoriadis DE. Corticotropin-releasing factor receptor subtype 2 in human colonic mucosa: down-regulation in ulcerative colitis. *World Journal of Gastroenterology*. 2013; 19:1416-1423.
53. Manousou P, **Kolios G**, Drygiannakis I, Koulentaki M, Pyrovolaki K, Voumvouraki A, Notas G, Bourikas L, Papadaki HA, Kouroumalis E. CXCR3 axis in patients with primary biliary cirrhosis: a possible novel mechanism of the effect of ursodeoxycholic acid. *Clinical and Experimental Immunology*. 2013; 172:9-15.
54. Pazaitou-Panayiotou K, Chemonidou C, Poupi A, Koureta M, Kaprara A, Lambropoulou M, Constantinidis TC, Galaktidou G, Koffa M, Kiziridou A, Kakolyris S, **Kolios G**, Kortsaris A, Chatzaki E. Gonadotropin-releasing hormone neuropeptides and receptor in human breast cancer: correlation to poor prognosis parameters. *Peptides*. 2013; 42:15-24.
55. Paschos KA, Chouridou E, Koureta M, Lambropoulou M, **Kolios G**, Chatzaki E. The corticotropin releasing factor system in the liver: expression, actions and possible implications in hepatic physiology and pathology. *Hormones*. 2013; 12:236-245.
56. Drygiannakis I, Valatas V, Sfakianaki O, Bourikas L, Manousou P, Kambas K, Ritis K, **Kolios G**, Kouroumalis E. Proinflammatory cytokines induce crosstalk between colonic epithelial cells and subepithelial myofibroblasts: implication in intestinal fibrosis. *Journal of Crohn's & Colitis*. 2013; 7:286-300.
57. Valatas V, He J, Rivollier A, **Kolios G**, Kitamura K, Kelsall BL. Host-dependent control of early regulatory and effector T-cell differentiation underlies the genetic susceptibility of RAG2-deficient mouse strains to transfer colitis. *Mucosal Immunology*. 2013; 6:601-611.

58. Balgkouranidou I, Karayiannakis A, Matthaios D, Bolanaki H, Tripsianis G, Tentis AA, Lianidou E, Chatzaki E, Fiska A, Lambropoulou M, **Kolios G**, Kakolyris S. Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival. *Clinical Chemistry and Laboratory Medicine*. 2013; 51:1505-1510.
59. Tzouvelekis A, Paspaliaris V, Koliakos G, Ntoliou P, Bouros E, Oikonomou A, Zissimopoulos A, Boussios N, Dardzinski B, Gritzalis D, Antoniadis A, Froudarakis M, **Kolios G**, Bouros D. A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. *Journal of Translational Medicine*. 2013; 11:171.
60. Drosos I, **Kolios G**. Stem cells in liver regeneration and their potential clinical applications. *Stem Cell Reviews*. 2013; 9:668-684.
61. Valatas V, Vakas M, **Kolios G**. The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases. *American Journal of Physiology. Gastrointestinal and Liver Physiology*. 2013; 305:G763- G785.
62. Lalidou F, **Kolios G**, Drosos GI. Bone infections and bone graft substitutes for local antibiotic therapy. *Surgical Technology International*. 2014; 24:353-362.
63. Karampelas T, Argyros O, Sayyad N, Spyridaki K, Pappas C, Morgan K, **Kolios G**, Millar RP, Liapakis G, Tzakos AG, Fokas D, Tamvakopoulos C. GnRH-Gemcitabine conjugates for the treatment of androgen-independent prostate cancer: pharmacokinetic enhancements combined with targeted drug delivery. *Bioconjugate Chemistry*. 2014; 25:813-823.
64. Lalidou F, **Kolios G**, Tavridou A, Drosos GI. Bone grafts as carriers for local antibiotic delivery for the treatment and prevention of bone infections. *Surgical Technology International*. 2014; 25:239-245.
65. Fouka E, Lamprianidou E, Arvanitidis K, Filidou E, **Kolios G**, Miltiades P, Paraskakis E, Antoniadis A, Kotsianidis I, Bouros D. Low-dose clarithromycin therapy modulates Th17 response in non-cystic fibrosis bronchiectasis patients. *Lung*. 2014; 192(6):849-855.
66. Drosos I, Tavridou A, **Kolios G**. New aspects on the metabolic role of intestinal microbiota in the development of atherosclerosis. *Metabolism: Clinical and Experimental*. 2015; 64:476-481.
67. Sertaridou E, Papaioannou V, **Kolios G**, Pneumatikos I. Gut failure in critical care: old school versus new school. *Annals of Gastroenterology*. 2015; 28:309-322.
68. Valatas V, Bamias G, **Kolios G**. Experimental colitis models: Insights into the pathogenesis of inflammatory bowel disease and translational issues. *European Journal of Pharmacology*. 2015; 759:253-264.
69. Fotiadis K, Filidou E, Arvanitidis K, Valatas V, Stavrou G, Basdanis G, Paspaliaris V, **Kolios G**, Kotzampassi K. Intraperitoneal application of phospholipids for the prevention of postoperative adhesions: a possible role of myofibroblasts. *Journal of Surgical Research*. 2015; 197(2):291-300.
70. **Kolios G**. Bin1 Antibodies for IBD Therapy: Is Permeability the Answer BAR None? *Digestive Diseases and Sciences*. 2016; 61:330-331.
71. **Kolios G**. Animal models of inflammatory bowel disease: how useful are they really? *Current Opinion in Gastroenterology*. 2016; 32:251-257.
72. Kotanidis L, Nikolettos K, Petousis S, Asimakopoulos B, Chatzimitrou E, **Kolios G**, Nikolettos N. The use of serum anti-Mullerian hormone (AMH) levels and antral follicle count (AFC) to predict the number of oocytes collected and availability of embryos for cryopreservation in IVF. *Journal of Endocrinological Investigation*. 2016; 39:1459-1464.

73. Bamias G, Filidou E, Goukos D, Valatas V, Arvanitidis K, Panagopoulou M, Kouklakis G, Daikos GL, Ladas SD, **Kolios G**. Crohn's disease-associated mucosal factors regulate the expression of TNF-like cytokine 1A and its receptors in primary subepithelial intestinal myofibroblasts and intestinal epithelial cells. *Translational Research*. 2017; 180:118-130.e2.
74. Panagopoulou M, Lambropoulou M, Balgkouranidou I, Nena E, Karaglani M, Nicolaidou C, Asimaki A, Konstantinidis T, Constantinidis TC, **Kolios G**, Kakolyris S, Agorastos T, Chatzaki E. Gene promoter methylation and protein expression of BRMS1 in uterine cervix in relation to high-risk human papilloma virus infection and cancer. *Tumour Biology*. 2017; 39:1010428317697557.
75. Valatas V, Filidou E, Drygiannakis I, **Kolios G**. Stromal and immune cells in gut fibrosis: the myofibroblast and the scarface. *Annals of Gastroenterology*. 2017; 30:393-404.
76. Dovrolis N, **Kolios G**, Spyrou G, Maroulakou I. Laying in silico pipelines for drug repositioning: a paradigm in ensemble analysis for neurodegenerative diseases. *Drug Discovery Today*. 2017; 22:805-813.
77. Gogou M, **Kolios G**. The effect of dietary supplements on clinical aspects of autism spectrum disorder: A systematic review of the literature. *Brain & Development*. 2017; 39:656-664.
78. Bouros E, Filidou E, Arvanitidis K, Mikroulis D, Steiropoulos P, Bamias G, Bouros D, **Kolios G**. Lung fibrosis-associated soluble mediators and bronchoalveolar lavage from idiopathic pulmonary fibrosis patients promote the expression of fibrogenic factors in subepithelial lung myofibroblasts. *Pulmonary Pharmacology & Therapeutics*. 2017; 46:78-87.
79. Karatzas E, Bourdakou MM, Kolios G, Spyrou GM. Drug repurposing in idiopathic pulmonary fibrosis filtered by a bioinformatics-derived composite score. *Scientific Reports*. 2017; 7:12569.
80. Dovrolis N, **Kolios G**, Spyrou GM, Maroulakou I. Computational profiling of the gut-brain axis: microflora dysbiosis insights to neurological disorders. *Briefings in Bioinformatics*. 2017; doi: 10.1093/bib/bbx154.
81. Karaglani M, Ragia G, Panagopoulou M, Balgkouranidou I, Nena E, **Kolios G**, Papanas N, Manolopoulos VG, Chatzaki E. Search for Pharmacoeigenetic Correlations in Type 2 Diabetes Under Sulfonylurea Treatment. *Experimental and Clinical Endocrinology & Diabetes*. 2018; doi: 10.1055/s-0043-121265.
82. Gogou M, **Kolios G**. Are therapeutic diets an emerging additional choice in autism spectrum disorder management? *World Journal of Pediatrics*. 2018; 14:215-223.
83. Brinkman DJ, Tichelaar J, Mokkink LB, Christiaens T, Likic R, Maciulaitis R, Costa J, Sanz EJ, Maxwell SR, Richir MC, van Agtmael MA. Key Learning Outcomes for Clinical Pharmacology and Therapeutics Education in Europe: A Modified Delphi Study. *Clinical Pharmacology and Therapeutics*. 2018; 104:317-325.
84. Papavramidis TS, Stavrou G, Papakostas P, Grosomanidis V, Kokkota S, Michalopoulos A, **Kolios G**, Kotzampassi K. Displacement of the Intra-gastric Balloon from the Fundus to the Antrum Results in Enhanced Weight Loss. *Obesity Surgery*. 2018; 28:2374-2378.
85. Stavrou G, Arvanitidis K, Filidou E, Fotiadis K, Grosomanidis V, Ioannidis A, Tsaousi G, Michalopoulos A, Kolios G, Kotzampassi K. Combined Enteral and Parenteral Glutamine Supplementation in Endotoxaemic Swine: Effects on Portal and Systemic Circulation Levels. *Medical Principles and Practice*. 2018; doi: 10.1159/000493481.
86. Filidou E, Valatas V, Drygiannakis I, Arvanitidis K, Vradelis S, Kouklakis G, **Kolios G**, Bamias G. Cytokine Receptor Profiling in Human Colonic Subepithelial Myofibroblasts: A Differential Effect of Th Polarization-Associated Cytokines in Intestinal Fibrosis. *Inflammatory Bowel Diseases*. 2018; 24:2224-2241.

87. Ioannidis A, Arvanitidis K, Filidou E, Valatas V, Stavrou G, Michalopoulos A, **Kolios G**, Kotzampassi K. The Length of Surgical Skin Incision in Postoperative Inflammatory Reaction. *Journal of the Society of Laparoendoscopic Surgeons*. 2018; 22. pii: e2018.00045.
88. Fasoulakis Z, **Kolios G**, Papamanolis V, Kontomanolis EN. Interleukins Associated with Breast Cancer. *Cureus*. 2018; 10:e3549.
89. Sertaridou EN, Chouvarda IG, Arvanitidis KI, Filidou EK, **Kolios GC**, Pnevmatikos IN, Papaioannou VE. Melatonin and cortisol exhibit different circadian rhythm profiles during septic shock depending on timing of onset: a prospective observational study. *Annals of Intensive Care*. 2018; 8:118.
90. Karatzas E, **Kolios G**, Spyrou GM. An Application of Computational Drug Repurposing Based on Transcriptomic Signatures. *Methods in Molecular Biology*. 2019; 1903:149-177.
91. Tsekoura M, Ioannidou M, Pana ZD, Haidich AB, Antachopoulos C, Iosifidis E, **Kolios G**, Roilides E. Efficacy and Safety of Echinocandins for the Treatment of Invasive Candidiasis in Children: A Meta-analysis. *Pediatric Infectious Disease Journal*. 2019; 38:42-49.
92. Tsaousi G, Stavrou G, Fotiadis K, Kotzampassi K, **Kolios G**. Implementation of phospholipids as pharmacological modalities for postoperative adhesions prevention. *European Journal of Pharmacology*. 2019; 842:189-196.
93. Panagopoulou M, Karaglani M, Balgkouranidou I, Pantazi C, **Kolios G**, Kakolyris S, Chatzaki E. Circulating cell-free DNA release in vitro: kinetics, size profiling, and cancer-related gene methylation. *Journal of Cellular Physiology*. 2019; doi: 10.1002/jcp.28097.
94. Dovrolis N, Drygiannakis I, Filidou E, Kandilogiannakis L, Arvanitidis K, Tentes I, **Kolios G**, Valatas V. Gut Microbial Signatures Underline Complicated Crohn's Disease but Vary Between Cohorts; An in-Silico Approach. *Inflammatory Bowel Diseases*. 2019; 25:217-225.
95. Panagopoulou M, Karaglani M, Balgkouranidou I, Biziota E, Koukaki T, Karamitrousis E, Nena E, Tsamardinos I, **Kolios G**, Lianidou E, Kakolyris S, Chatzaki E. Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers. *Oncogene*. 2019; 38:3387-3401.
96. Valatas V, Kolios G, Bamias G. TL1A (TNFSF15) and DR3 (TNFRSF25): a co-stimulatory system of cytokines with diverse functions in gut mucosal immunity. *Frontiers in Immunology*. 2019; 10:583.
97. Dovrolis N, Filidou E, Kolios G. Systems biology in inflammatory bowel diseases: on the way to precision medicine. *Annals of Gastroenterology*. 2019; 32:233-246.
98. Gazouli M, Dovrolis N, Franke A, Spyrou GM, Sechi LA, Kolios G. Differential genetic and functional background in inflammatory bowel disease phenotypes of a Greek population: a systems bioinformatics approach. *Gut Pathogens*. 2019; 11:31.
99. Paspaliaris V, **Kolios G**. Stem cells in Osteoporosis: From Biology to New Therapeutic Approaches. *Stem Cells International*. 2019; 1730978:1-16.
100. Gogou M, **Kolios G**. Nutritional Supplements During Gestation and Autism Spectrum Disorder: What Do We Really Know and How Far Have We Gone? *Journal of the American College of Nutrition*. 2019; Jul 18:1-11.
101. Mantziaris V, **Kolios G**. Gut Microbiota, Atherosclerosis, and Therapeutic Targets. Critical Pathways in Cardiology. 2019; 18:139-142.
102. Karatzas E, Minadakis G, **Kolios G**, Delis A, Spyrou GM. A Web Tool for Ranking Candidate Drugs Against a Selected Disease Based on a Combination of Functional and Structural Criteria. *Computational and Structural Biotechnology Journal*. 2019; 17:939-945.

103. Papaioannou VE, Sertaridou EN, Chouvarda IG, **Kolios GC**, Pneumatikos IN. Determining rhythmicity and determinism of temperature curves in septic and non-septic critically ill patients through chronobiological and recurrence quantification analysis: a pilot study. *Intensive Care Medicine Experimental*. 2019; 7:53.
104. Karaglani M, Tzitzikou E, Tottas S, Kougioumtzis I, Arvanitidis K, **Kolios G**, Chatzaki E, Drosos GI. Gentamycin elution from polymethylmethacrylate and bone graft substitute: Comparison between commercially available and home-made preparations. *Journal of Orthopaedics*. 2019; 19:9-13.
105. Dovrolis N, Michalopoulos G, Theodoropoulos GE, Arvanitidis K, **Kolios G**, Sechi LA, Eliopoulos AG, Gazouli M. The Interplay between Mucosal Microbiota Composition and Host Gene-Expression is Linked with Infliximab Response in Inflammatory Bowel Diseases. *Microorganisms*. 2020; pii: E438.
106. Koureta M, Karaglani M, Panagopoulou M, Balgkouranidou I, Papadaki-Anastasopoulou A, Zarouchlioti C, Dekavallas S, **Kolios G**, Lambropoulou M, Baritaki S, Chatzaki E. Corticotropin Releasing Factor Receptors in breast cancer: Expression and activity in hormone-dependent growth in vitro. *Peptides*. 2020; 170316.
107. Karatzas E, Zachariou M, Bourdakou MM, Minadakis G, Oulas A, **Kolios G**, Delis A, Spyrou GM. PathWalks: Identifying pathway communities using a disease-related map of integrated information. *Bioinformatics*. 2020; pii: btaa291.
108. Varbobitis I, Kokkotis G, Gizis M, Perlepe N, Laoudi E, Bletsas M, Bekiari D, Koutsounas I, Kounadis G, Xourafas V, Lagou S, **Kolios G**, Papakonstantinou I, Bamias G. The IBD-F Patient Self-Assessment Scale Accurately Depicts the Level of Fatigue and Predicts a Negative Effect on the Quality of Life of Patients with IBD in Clinical Remission. *Inflammatory Bowel Diseases*. 2020; Aug 7:izaa201.
109. Karamitrousis E, Balgkouranidou I, Xenidis N, Amarantidis K, Biziota E, Koukaki T, Trypsianis G, Karayiannakis A, Bolanaki H, Chatzaki E, **Kolios G**, Lianidou E, Lambropoulou M, Kakolyris S. Association between SOX17, Wif-1 and RASSF1A promoter methylation status and response to chemotherapy in patients with metastatic gastric cancer. *Clinical Chemistry and Laboratory Medicine*. 2020; in press.

Νοέμβριος 2020
Γεώργιος Κολιός, MD PhD